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Objective: The present study investigated the impact of overall obesity defined by BMI and abdominal obesity
defined by WC on vascular atherosclerotic changes in obese and normal weight diabetic subjects.
Design and methods: 285 subjects were divided according to presence diabetes mellitus (DM) and obesity: Group
1 included 144 nonobese subjects without DM; Group 2 consisted of 141 type 2 diabetic patients. Then diabetic
patients were divided into two groups according to presence of overall obesity, defined by BMI and furthermore,
abdominal obesity, defined by waist circumference (WC). Pulse wave velocity (PWV) and augmentation index (AI)
were performed using SphygmoCor (version 7.1, AtCor Medical, Sydney, Australia).
Results: Between Group Comparisons by BMI: Diabetic subjects with and without overall obesity did not differ from
one another in terms of AI and PWV.
Between Group Comparisons by WC: AI as well as PWV increased consistently from Group 1 to Group 3, AI and PWV
were significantly higher in abdominally obese diabetic subjects than in the diabetics without abdominal obesity (p
= 0.008 and p = 0.013, respectively). Significant by-group differences in PWV and AI persisted after adjustment for
age, sex, blood pressure, fasting glucose and BMI.
Conclusions: Abdominal obesity defined by WC was associated with significantly higher AI and PWV in in both
diabetic men and women; whereas overall obesity defined by BMI did not predict adverse vascular changes in this
study population. Abdominal obesity was associated with an adverse effect on blood vessels, independently of age,
sex, blood pressure, fasting glucose and BMI.Introduction
In diabetes, arterial stiffening is consistently observed
across all age groups and may contribute, in part, to the
excess cardiovascular morbidity and mortality observed
in these patients [1,2]. Several pre-existing risk factors
including hypertension, dyslipidemia and obesity may
further increase the cardiovascular risk associated with
hyperglycemia, leading to excess CVD risk at an earlier
age. Physiopathology that links increased adiposity as
well as diabetes to arterial stiffening is not precisely
known. One suggested mechanism is through insulin re-
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article, unless otherwise stated.2 diabetes mellitus. A reciprocal relationship exists be-
tween insulin resistance and endothelial dysfunction,
considered to be a key initiating step in the atheroscler-
otic cascade [3,4]. However, not all type 2 diabetic indi-
viduals demonstrate similar insulin resistance as well as
cardiovascular risk factor profiles. Obese type 2 diabetics
have significantly decreased insulin-stimulated glucose
disposal and insulin sensitivity index, confirming that
insulin resistance is the major contributor to the patho-
genesis of hyperglycemia in obese subjects with type 2
DM , whereas lean type 2 diabetics are characterized
primarily by a defect in insulin secretion [5,6]. Cur-
rently, there is no consistent evidence regarding differ-
ences in term of cardiovascular morbidity and mortality
between obese and nonobese diabetic patients. Even
less information is available regarding vascular impact
of different obesity anthropometric indexes such asentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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in obese and normal weight diabetic subjects.
Estimation of arterial stiffness has been reported to be a
useful method for assessment of early preclinical athero-
sclerosis [7]. PWV, which is associated with higher risk of
cardiovascular morbidity and mortality and AI, which re-
cently been considered as a valid biomarker, provide valu-
able information regarding vascular health [8,9].
The present study was designed to investigate the
impact of overall obesity defined by BMI and abdom-
inal obesity defined by WC on vascular atherosclerotic
changes in obese and normal weight diabetic subjects.
Materials and methods
Subjects
The study group consisted of 285 Caucasian subjects,
(185 women and 100 men, mean age 61.4+/-10.9 years)
who were recruited from the outpatient metabolic
clinic and evaluated for the study. The study partici-
pants were divided into two groups according to pres-
ence of type 2 diabetes mellitus: 144 nonobese subjects
without DM (DM-Ob-) defined as the control group
and 141 diabetic subjects. Study participants were clas-
sified as diabetic if fasting plasma glucose level was
≥126 mg/dl on at least two blood samples, or if they
were treated with antidiabetic medications. Then, dia-
betic patients were divided into two groups by presence
of overall obesity, according to BMI: Group 2 consisted
of 62 diabetic non obese subjects (DM +Ob-) and
Group 3 contained 79 participants with diabetes and
obesity (DM +Ob-). Obesity was defined using World
Health Organization criteria (BMI > =30 kg/m2).
Additionally, diabetic subjects were divided into two
groups according to presence of abdominal obesity. We
classified male participants with WC >102 cm and female
participants with WC >88 cm as subjects with abdominal
obesity (AOb). Group 1 included 138 nondiabetic subjects
without abdominal obesity (DM- AOb-) defined as the
control group, Group 2 consisted of 67 diabetic subjects
without abdominal obesity (DM- AOb-) and Group 3 con-
tained 74 participants with diabetes and abdominal obesity
(DM+AOb+). Patients included in the study had been
stabilized according to their previous medical treatment in
the outpatient clinic for up to three months before en-
trance to the study. This study had been approved by the
local scientific committee, and all participants gave in-
formed consent before entering the study.
Biochemical parameters
Blood sampling for full chemistry and metabolic parame-
ters, including total cholesterol, HDL and LDL choles-
terol, triglycerides, fasting glucose, HbA1C, fasting insulin,
CRP and serum aldosterone and plasma renin activity,
was performed. Glucose was measured using the Aerosetchemistry system (Abbott Diagnostics), high-density lipo-
protein cholesterol (HDL) and triglycerides were assayed
using an Aeroset automated analyzer (Abbott Diagnostics,
Berkshire, UK), low-density lipoprotein cholesterol (LDL)
was calculated using Friedewald’s formula and insulin was
measured using an immunometric assay specific for hu-
man insulin (Invitron, Monmouth, UK). Serum aldoster-
one and plasma renin activity were measured in a sitting
position using commercially available radioimmunoassay.
The lower limits of the serum aldosterone and plasma
renin activity were 0.6 ng/dl and 0.1 ng/ml/h, respectively.
The samples were measured in duplicate. Homeostasis
model assessment-insulin resistance (HOMA-IR) was cal-
culated by the following formula: fasting plasma insulin
(mU/ml) × fasting plasma glucose (mg/dl)/405.
Blood pressure and arterial stiffness measurement
The hemodynamic measurements were performed be-
tween 8 and 11 AM in a quiet room at 20–23°C after rest-
ing for 15 min. Blood pressure (BP) was measured using
an automated digital oscillometric device (Omron model
HEM 705-CP, Omron Corporation, Tokyo, Japan), and a
mean of three readings was taken. Pulse wave velocity was
measured by recording of the right carotid and the right
radial artery pulse waveforms by two pressure transducers
using the SphygmoCor Vx PWV System. The radial pres-
sure waveform was recorded and subsequently trans-
formed by using a validated generalized transfer function
incorporated in the SphygmoCor (version 7.1, AtCor Med-
ical, Sydney, Australia) to give an estimate of the corre-
sponding central ascending aortic pulse wave. With the
integral software, the central augmented pressure was cal-
culated as the difference between the early and late systolic
peaks of the estimated central pressure waveform. Central
aortic augmentation index (AI) was calculated as the aortic
augmented pressure expressed as a percentage of the pulse
pressure and automatically adjusted to heart rate of 75
beats/minute. This technique, which has been validated for
its reproducibility and used extensively, had been accepted
as substantially equivalent to aortic pressure measured by
invasive catheterization [10].
Statistical analysis
Analysis of data was carried out using SPSS 11.0 statis-
tical analysis software (SPSS Inc., Chicago, IL, USA).
For continuous variables, such as hemodynamic, arter-
ial compliance and chemistry parameters, descriptive
statistics were calculated and reported as mean ± stand-
ard deviation. Normalcy of distribution of continuous
variables was assessed using the Kolmogorov-Smirnov
test (cut off at p = 0.01). Continuous variables were
compared across groups using one-way analysis of vari-
ance (ANOVA). Variables for which across-group dif-
ferences were detected underwent post hoc pairwise
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such as comorbidities and prescribed medications were
described using frequency distributions and are presented
as frequency (%). Categorical variables were compared
across groups using the chi-square test (exact as needed).
Pearson’s correlation analysis was used to calculate correl-
ation coefficients to describe associations between con-
tinuous variables. Pulse wave velocity and augmentation
index were modeled using multiple linear regression ana-
lysis with a backward, stepwise approach. For inclusion,
the probability of F was set at 0.05, and at 0.10, for exclu-
sion. Variables for inclusion were identified in univariate
associations with the outcome of interest. All tests are
two-sided and considered significant at p < 0.05.
Results
Between group comparisons by BMI
Demographic and clinical characteristics of the three
groups are presented in Table 1. As expected, BMI was
significantly higher in Group 3, as compared to Group 1
and Group 2; whereas, Groups 1 and 2 did not differ fromTable 1 Demographic and clinical characteristics of study gro
Variables Group 1
DM-Ob-
Age (years) 56.2 ±12.2







CC Blocker use 14.6%
Beta blocker use 16.76%
Statin use 13.2%
Fasting plasma glucose(mg/dl) 93.4 ±9.8
HbA1C (%) 5.9 ±0.4
Low density lipoprotein cholesterol (mg/dl) 119.0 ±31
High density lipoprotein cholesterol (mg/dl) 53.7 ±12.0
Triglycerides (mg/dl) 119.0 ±59
C-reactive protein (mg/dl) 0.3 ±0.3
HOMA IR 1.9 ±1.2
Creatinine (mg/dl) 0.9 ±1.2
Systolic blood pressure (mmHg) 124.7 ±15
Diastolic blood pressure (mmHg) 69.3 ±9.0
AI(%) 29.6 ±9.6
PWV (m/sec) 6.1 ±1.0
By-group comparisons made using one way analysis of variance (ANOVA) simultane
*p-value vs. group 1 (significant at the 0.05 level).one another. However, Group 1 and Group 2 differed sig-
nificantly in terms of age, presence HTN, smoking and
concomitant medications. As can be seen, parameters,
such as total, LDL-, HDL- cholesterol, triglycerides, fasting
glucose, HbA1C and HOMA-IR, differed significantly be-
tween Group 1 and Group 3. CRP levels and parameters
of glucose homeostasis such as fasting glucose and
HbA1C were significantly higher and HOMA-IR was mar-
ginally higher in obese diabetic subjects compared to non
obese diabetics. Systolic as well as diastolic blood pressure
values increased consistently from Group 1 to Group 3.
As shown in Figure 1 and Table 1, diabetic subjects
with and without overall obesity did not differ from one
another in terms of AI and PWV (p = 0.064). As ex-
pected, non obese subjects without diabetes (DM-Ob-)
had significantly lower PWV as well as AI than the two
diabetic groups (p < 0.0001).
Between group comparisons by WC
As can be seen in Table 2, WC was significantly higher in
Group 3, as compared to Group 2 and Group 3; whereas,ups defined by BMI
Group 2 Group 3
DM + Ob- DM + Ob+
66.7 ±8.4* 61.4 ±8.7










147.9 ±43.9* 164.4 ±58.4*
7.4 ±1.4* 8.1 ±1.7*
.6 99.0 ±30.3 93.8 ±29.3*
46.3 ±10.4* 45.1 ±13.1*
.1 144.3 ±104.8 166.0 ±109.3*
0.5 ±0.8* 0.9 ±1.3*
6.0 ±13.0 10.9 ±17.7*
1.1 ±0.9* 1.0 ±0.5*
.6 141.4 ±19.9* 154.1 ±20.1*
74.1 ±9.6* 78.7 ±9.9*
36.8 ±8.8* 35.6 ±11.3*
7.5 ±2.7* 7.5 ±3.2*
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Figure 1 AI and PWV parameters by overall obesity, according to BMI.
Table 2 Demographic and clinical characteristics of study groups defined by WC
Variables Group 1 Group 2 Group 3
DM-AOb- DM + AOb- DM + AOb+
Age (years) 59.2 ±12.4 65.1 ±8.9* 62.0 ±8.7
BMI (kg/m2) 24.9 ±2.2 26.8 ±4.1 33.1 ±4.8*
Hypertension 10.9% 59.7%* 67.6%*
Smoker 8.7% 20.9%* 16.2%
Aspirin use 5.9% 49.3%* 41.9%*
Insulin use 0.0% 26.9%* 39.2%*
Metformin use 0.0% 74.6%* 74.3%*
ACEI/ARB use 16.7% 59.7%* 67.6%*
CC Blocker use 0.0% 35.8%* 36.8%*
Beta blocker use 15.2% 44.8%* 50%*
Statin use 13.8% 64.2%* 62.2%*
Fasting plasma glucose(mg/dl) 93.5 ±9.9 148.3 ±44.5* 166.0 ±57.6*
HbA1C (%) 5.9 ±0.4 7.5 ±1.6* 8.2 ±1.6*
Low density lipoprotein cholesterol (mg/dl) 119.8 ±31.1 89.1 ±27.6* 94.5 ±31.4*
High density lipoprotein cholesterol (mg/dl) 53.6 ±12.0 46.4 ±11.1* 44.6 ±12.4*
Triglycerides (mg/dl) 121.0 ±59.9 156.5 ±108.5* 156.6 ±105.2*
C-reactive protein (mg/dl) 0.3 ±0.3 0.5 ±0.5 0.9 ±1.5*
HOMA-IR 2.0 ±1.1 6.03 ±12.3* 10.8 ±17.8*
Creatinine (mg/dl) 0.9 ±0.2 1.0 ±0.4 1.1 ±0.7*
Systolic blood pressure (mmHg) 119.2 ±13.9 134.0 ±18.6* 153.3 ±20.6*
Diastolic blood pressure (mmHg) 67.2 ±8.6 73.1 ±9.7 78.4 ±10.3*
AI (%) 29.2 ±9.4 34.0 ±8.9* 38.8 ±10.4*
PWV(m/sec) 6.0 ±0.9 6.9 ±1.8* 7.9 ±3.5*
By-group comparisons made using one way analysis of variance (ANOVA).
simultaneously comparing all three groups.
*p-value vs. group 1 (significant at the 0.05 level).
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Systolic BP 0.540 0.695
Fasting glucose 0.038 0.713
BMI 0.781 0.054
Group* 0.000 0.000
Multiple linear regression analysis was arrived at using a backward, stepwise
approach with probability of F = 0.05 for entry and 0.15 for removal from
the model.
*Group according to WC.
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level, fasting glucose, HbA1C and blood pressure in-
creased consistently from Group 1 to Group 3.
As shown in Figure 2 and Table 2, AI as well as PWV
differed significantly between groups (p < 0.0001), such
that both of them were significantly lower in non-obese
non diabetic subjects than in the diabetic subjects with
and without obesity. Groups 2 and 3 differed signifi-
cantly from one another: AI and PWV were signifi-
cantly higher in obese diabetic subjects than in the
diabetic subjects without abdominal obesity (p = 0.008
and p = 0.013, respectively).
General linear model of AI and PWV
Univariate GLM analysis was carried out to control for
variables, differed significantly by groups (Table 3). This
analysis was modeled using multiple linear regression
analysis with a backward, stepwise approach. For inclu-
sion, the probability of f was set at 0.05, and at 0.10, for
exclusion. Included in the model of PWV were age, sex,
blood pressure, fasting glucose and BMI. Additionally,
group by WC was included as a fixed factor. The model of
PWV was significant (p < 0.0001) and explained 14.5% of
the variability in this outcome. Significant by-group differ-
ences in PWV persisted even after adjustment. BMI wasn’t
the significant independent predictor of PWV.
Additionally, general linear model of AI was carried out.
The model was significant (p < 0.0001) and explained
30.8% of the variability in this outcome. Age, sex, blood
pressure, fasting glucose and BMI were included as a
covariate in this model. Significant by-group differences
in AI persisted even after adjustment. The model itself
was significant (p < 0.0001) and explained the variability
of about 30.8% in AI.
Discussion
In the present study, abdominal obesity defined by WC
was associated with significantly higher AI and PWV in
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Figure 2 AI and PWV parameters by abdominal obesity, according todid not predict adverse vascular changes in this study
population. Abdominal obesity was associated with an ad-
verse effect on blood vessels, independently of age, sex,
blood pressure, fasting glucose and BMI. Combination of
diabetes mellitus and abdominal obesity, but not overall
obesity, was associated with significant deterioration in
terms of arterial stiffness parameters.
Findings of the present study concur with recently pub-
lished data demonstrated stronger association of abdom-
inal obesity than BMI with total mortality among elderly
subjects at high risk of cardiovascular disease, particularly
among diabetic participants [11]. Additionally, it was
shown that the measures of abdominal obesity correlates
better than BMI with arterial stiffness evaluated by PWV,
and with subclinical atherosclerosis evaluated by C-IMT,
in healthy, diabetics and hypertensive subjects [12].
Previous clinical and experimental data show that ab-
dominal adipose tissue can play an important role in the
development of diabetes mellitus and it can also increase
the risk of cardiovascular and all-cause mortality [13,14].
Body fat distribution is one of the major determinants of
metabolic health, and visceral adiposity has a stronger
correlation with metabolic abnormalities and cardiovas-
cular disease than subcutaneous adipose tissue [15-17].












Aortic augmentation index (%)
Group 1 Group 2 Group 3
WC.
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plays an important role in insulin sensitivity, inflamma-
tion, lipid metabolism and atherogenesis. It was shown
that low plasma adiponectin levels are significantly corre-
lated with endothelial dysfunction, increased intima media
thickness and progression of coronary artery calcification
independently of other cardiovascular risk factors [18,19].
Leptin as well is involved in insulin sensitivity, angiogen-
esis, vascular and endothelial function [20]. Moreover,
novel and traditional cardiovascular risk factors such as
asymmetric dimethyl-arginine ADMA levels and LDL-
cholesterol are strongly associated with increased arterial
stiffness among pre-diabetic subjects [21].
It has been demonstrated that excess body fat, abdom-
inal visceral fat, and larger waist circumference have been
associated with accelerated arterial stiffening independ-
ently of blood pressure levels, ethnicity and age in older
adults [22]. Moreover, both WC and sagittal abdominal
diameter (SAD) are associated with subclinical organ
damage such as PWV and carotid intima-media thickness
and provided information on inflammation, atheroscler-
osis and arterial stiffness in type 2 diabetic patients [23].
However, it has also been reported that SAD was more in-
dependent in predicting arterial stiffness over time, com-
pared with WC, in middle-aged men and women with
type 2 diabetes [24], Recently , it has been demonstrated
that neck circumference is associated with an increased
PWV in hypertensive adults, independent of other meta-
bolic risk factors [25].
The pathophysiology that links abdominal adiposity
to arterial stiffening is not precisely known. One sug-
gested mechanism is through insulin resistance, which
commonly accompanies obesity. A reciprocal relation-
ship exists between insulin resistance and endothelial
dysfunction, considered to be a key initiating step in
the atherosclerotic cascade. Reduced insulin action in
peripheral tissue impairs endothelium-dependent vaso-
dilatation [3] and increases the local activity of a variety
of growth factors in vascular tissue [26,27], promoting
collagen production and the development of vascular
smooth muscle cell (VSMC) hypertrophy [28]. It has
been shown that obese young adults who both lower
their insulin levels and lose weight showed the greatest
improvement in vascular stiffness [29]. In addition, the
pro-inflammatory state typical of obesity stimulates re-
active oxygen species production, inhibits nitric oxide
production by reducing levels of NO synthase in vascu-
lar smooth muscle cells and endothelial cells and pro-
motes endothelial apoptosis [30,31].
In concurrence with previous studies, the present study
did not detect the gender-related differences in the associ-
ation between abdominal obesity measures and arterial
stiffness in diabetic men and women. However, it has also
been reported, that increasing BMI, WC, visceral fat areaand fat mass were independently associated with higher
PWV in women, but not in men, after adjustment for age,
hypertension and type 2 diabetes [32].
The individuals with normal weight and increased levels
of abdominal obesity could be genetically predisposed to
the development of diabetes mellitus as well as CV dis-
ease. Since vascular changes inflicted by multiple environ-
mental and genetic factors, develop years before an event,
detection of vascular damage can serve as a predictor of
future cardiovascular complications. In the present study,
WC was a significant independent predictor of early vas-
cular adverse changes detected by using PWV and AI.
Therefore, abdominal obesity defined by WC, might be a
better predictor of arterial stiffness as well as future car-
diovascular events in diabetic patients.
In conclusion, the present study demonstrated that ab-
dominal obesity, defined by WC is associated with an ad-
verse effect on blood vessels, independently of age, sex,
and blood pressure, parameters of glucose homeostasis
and BMI in type 2 diabetic patients. Combination of dia-
betes mellitus and increased WC, but not increased BMI,
was associated with significant deterioration in terms of
arterial stiffness parameters in this study population. The
precise mechanisms for these vascular changes, as well as
overall clinical impact of WC reduction on cardiovascular
outcomes deserve further investigation.
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